title: Beneficial effects of pinacidil on blood lipids: comparisons with prazosin and placebo in patients with hypertension. Pinacidil-Prazosin and Pinacidil-Placebo Research Groups, Lilly Research Laboratories.
abstract: In two randomized, double-blind clinical trials comparing pinacidil with prazosin and with placebo in patients with hypertension, a number of statistically significant and potentially beneficial effects on blood lipids were detected in the patients taking pinacidil. Patients treated with pinacidil exhibited significant average decrements from baseline in concentrations of total and low-density lipoprotein cholesterol and triglycerides and a significant average increment in high-density lipoprotein cholesterol. The mean effects seen in the pinacidil group were significantly greater than those in the placebo group for both total cholesterol (-9.8 vs +4.2 mg/dl, p less than 0.001) and triglycerides (-21.6 vs +8.6 mg/dl, p less than 0.001). The effects seen in patients given pinacidil were also significantly greater than those seen in the patients treated with prazosin for both high-density lipoprotein cholesterol (+3.6 vs -1.0 mg/dl, p = 0.002) and triglycerides (-14.8 vs +30.3 mg/dl, p less than 0.001). Negative effects of hydrochlorothiazide and propranolol on blood lipids were not apparent in patients given pinacidil. Thus, pinacidil treatment of hypertension is associated with a beneficial effect on blood lipids, which may be of clinical significance.
authors.affiliation: Lilly Laboratory for Clinical Research, Wishard Memorial Hospital, Indianapolis, IN 46202.
authors.forename: F W
authors.initials: FW
authors.lastname: Rockhold
authors.forename: M R
authors.initials: MR
authors.lastname: Goldberg
authors.forename: W L
authors.initials: WL
authors.lastname: Thompson
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000097:blood; D004311:Double-Blind Method; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D020110:Pinacidil; D011224:Prazosin / Q000627:therapeutic use*; D011433:Propranolol / Q000627:therapeutic use; D011897:Random Allocation; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood*
chemical_list: D000959:Antihypertensive Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006146:Guanidines; D014280:Triglycerides; D006852:Hydrochlorothiazide; D020110:Pinacidil; D002784:Cholesterol; D011433:Propranolol; D011224:Prazosin